Topics
November/December 2018 | Subfocus: The Best Of Retina
A Review of All Things Retina
Looking back at some of the field's exciting developments over the past 12 months.
Michele Corry
June 22, 2026
Atsena Doses First Patient in Phase 3 LIGHTHOUSE Trial of Gene Therapy for XLRS
June 19, 2026
Lexitas Pharma Services Named Octane Preferred Advisor
Potential Drug Signals Linked to Wet AMD Identified in Integrative Analysis
Foundation Fighting Blindness Receives $1 Million Commitment to Advance Gene-Agnostic IRD Therapies
May/June 2026 Insert
Editorially Independent Content, Supported With Advertising From Astellas
Supported by Zeiss
Editorially independent supported by Abbvie and Regenxbio
May/June 2026 Supplement
Free Print Subscription
Email Newsletter
Conference Calendar
